Salib R J, Lau L C, Howarth P H
Department of Respiratory Cell & Molecular Biology, Allergy Inflammation Research Division, School of Medicine, University of Southampton, Southampton UK.
Clin Exp Allergy. 2005 Jun;35(6):811-9. doi: 10.1111/j.1365-2222.2005.02258.x.
The epithelial accumulation of mast cells is a feature of allergic rhinitis and this has been linked to the expression of the known mast cell chemoattractant transforming growth factor-beta (TGF-beta) at this site. Little is known concerning the regulation of TGF-beta gene expression or protein release by nasal epithelial cells. To address this we have utilized the RPMI 2650 human nasal epithelial cell line, which has some features that closely resemble normal nasal epithelium and has been reported to secrete a TGF-beta-like molecule.
To investigate the regulation of TGF-beta gene expression and protein secretion in RPMI 2650 nasal epithelial cells following exposure to allergens (house dust mite (HDM) and grass pollen) and mast cell associated T-helper type 2 (Th2) cytokines (IL-4, IL-13, and TNF-alpha). Methods Light and scanning electron microscopy was used to evaluate the morphology of RPMI 2650 cells in culture, enzyme-linked immunosorbent assay was used to investigate their TGF-beta secretory capacity and the identification of the TGF-beta isotype(s) involved, flow cytometry was used to demonstrate the presence of TGF-beta receptors on the RPMI 2650 cells, and the quantitative real-time TaqMan PCR was used to measure TGF-beta gene expression.
TGF-beta(2) was identified as the main isotype secreted by the RPMI 2650 cells. HDM allergens and TNF-alpha increased both TGF-beta gene expression and protein release from these cells, whereas grass pollen, IL-4, and IL-13 were without effect.
The RPMI 2650 nasal epithelial cell line represents a valid in vitro model to evaluate the regulation of TGF-beta biology. In this system HDM allergens have stimulatory activity that is fundamentally different from that of grass pollen allergens, and the Th2 cytokines IL-4 and IL-13 are without effect. The ability of TNF-alpha to up-regulate both TGF-beta gene expression and protein release indicates that mast cell-epithelial interactions concerning TGF-beta are bi-directional and this may be fundamental to epithelial immunoregulation. The availability of a model system, such as the RPMI 2650 cells, will enable the early evaluation of future novel and targeted interventions directed toward the aberrant responses of upper airway structural cells.
肥大细胞在上皮中的积聚是变应性鼻炎的一个特征,这与已知的肥大细胞趋化因子转化生长因子-β(TGF-β)在此部位的表达有关。关于鼻上皮细胞对TGF-β基因表达或蛋白释放的调控知之甚少。为解决这一问题,我们利用了RPMI 2650人鼻上皮细胞系,该细胞系具有一些与正常鼻上皮非常相似的特征,并且据报道能分泌一种TGF-β样分子。
研究RPMI 2650鼻上皮细胞在暴露于变应原(屋尘螨(HDM)和草花粉)以及肥大细胞相关的2型辅助性T细胞(Th2)细胞因子(IL-4、IL-13和TNF-α)后TGF-β基因表达和蛋白分泌的调控情况。方法 采用光学显微镜和扫描电子显微镜评估培养的RPMI 2650细胞的形态,采用酶联免疫吸附测定法研究其TGF-β分泌能力及所涉及的TGF-β同种型的鉴定,采用流式细胞术证明RPMI 2650细胞上存在TGF-β受体,采用定量实时TaqMan PCR法测定TGF-β基因表达。
TGF-β(2)被鉴定为RPMI 2650细胞分泌的主要同种型。HDM变应原和TNF-α增加了这些细胞的TGF-β基因表达和蛋白释放,而草花粉、IL-4和IL-13则无此作用。
RPMI 2650鼻上皮细胞系是评估TGF-β生物学调控的一个有效的体外模型。在这个系统中,HDM变应原具有与草花粉变应原根本不同的刺激活性,Th2细胞因子IL-4和IL-13无作用。TNF-α上调TGF-β基因表达和蛋白释放的能力表明,肥大细胞与上皮细胞之间关于TGF-β的相互作用是双向的,这可能是上皮免疫调节的基础。像RPMI 2650细胞这样的模型系统的可用性将有助于对未来针对上呼吸道结构细胞异常反应的新型靶向干预措施进行早期评估。